Article
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Expert opinion on investigational drugs - 1 Aug 2020
Morabito Fortunato, Gentile Massimo, Monti Paola, Recchia Anna Grazia, Menichini Paola, Skafi Mamdouh, Atrash Moien, De Luca Giuseppa, Bossio Sabrina, Al-Janazreh Hamdi, Galimberti Sara, Salah Zaidoun, Morabito Lucio, Mujahed Alham, Hindiyeh Musa, Dono Mariella, Fais Franco, Cutrona Giovanna, Neri Antonino, Tripepi Giovanni, Fronza Gilberto, Ferrarini Manlio
Abstract excerpt
INTRODUCTION: Patients with TP53 dysfunction, assessed by del(17p) or TP53 mutations, respond poorly to chemo-immunotherapy and fare better with the new therapies (BCR and BCL-2 inhibitors); however, it is unclear whether their response is similar to that of patients without anomalies or whether there is currently an adequate determination of TP53 dysfunction. AREA COVERED: A literature search was undertaken on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.